Back to Search
Start Over
COVID-19, severe asthma, and biologics.
- Source :
-
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2020 Sep; Vol. 125 (3), pp. 357-359.e1. Date of Electronic Publication: 2020 Jun 14. - Publication Year :
- 2020
- Subjects :
- Acetates therapeutic use
Amoxicillin-Potassium Clavulanate Combination therapeutic use
Asthma complications
Asthma immunology
Asthma virology
Azithromycin therapeutic use
Betacoronavirus immunology
Budesonide therapeutic use
COVID-19
Convalescence
Coronavirus Infections complications
Coronavirus Infections immunology
Coronavirus Infections virology
Cyclopropanes
Eosinophils drug effects
Eosinophils immunology
Eosinophils virology
Female
Humans
Hydroxychloroquine therapeutic use
Ipratropium therapeutic use
Male
Middle Aged
Pandemics
Pneumonia, Viral complications
Pneumonia, Viral immunology
Pneumonia, Viral virology
Quinolines therapeutic use
SARS-CoV-2
Sulfides
Treatment Outcome
Adrenergic beta-2 Receptor Antagonists therapeutic use
Anti-Asthmatic Agents therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Asthma drug therapy
Betacoronavirus pathogenicity
Coronavirus Infections drug therapy
Pneumonia, Viral drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1534-4436
- Volume :
- 125
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- Publication Type :
- Report
- Accession number :
- 32553608
- Full Text :
- https://doi.org/10.1016/j.anai.2020.06.012